Shots:
In the P-III study participants (n=1795) were randomly assigned in 1:1 to receive lecanemab (10 mg/kg Q2W, IV, n=898) or PBO (n=897) and results were published in the New England Journal of Medicine
The result showed the mean CDR-SB score at baseline was ~3.2 in both groups, the adjusted least-squares mean change from baseline @18mos. was (1.21 vs 1.66) also greater reduction were observed in brain amyloid burden with lecanemab vs. PBO
Lecanemab (BAN2401), an anti-amyloid beta (Aβ) protofibril antibody for the treatment of mild cognitive impairment due to Alzheimer’s disease with confirmed presence of amyloid pathology in the brain
Ref: PRNewswire | Image: Biogen
